Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-06 02:02 UTC

BIOMED PULSE

Sunday, July 6, 2026

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, making it the dominant global health emergency of 2026. Outlook is grave but active: the PARTNERS treatment trial opened patient enrollment in DRC on July 2, and WHO just cleared the first rapid diagnostic test for Bundibugyo virus under Emergency Use Listing.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS — DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, the DRC alone has recorded 1,460 confirmed Bundibugyo virus disease (BVD) cases and 452 confirmed deaths, with cross-border transmission continuing in Uganda. [1]
  • WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 17, 2026; the IHR Emergency Committee confirmed it does not yet meet pandemic emergency criteria. [2] [3]
  • Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, 2026, seeking to raise USD 518 million to support African countries. [4]
  • WHO published its first-ever comprehensive clinical management guidelines for all filovirus diseases, including all Ebola types and Marburg, on June 17, 2026. [5]
  • CDC has active enhanced Ebola entry screening at Washington Dulles International Airport and Atlanta Hartsfield-Jackson Airport for travelers arriving from affected regions. [6] [7]

EBOLA — DIAGNOSTICS BREAKTHROUGH

  • On July 2, 2026, WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing, enabling rapid genetic detection in blood samples. [8]

EBOLA — FIRST TREATMENT TRIAL OPENS

  • The PARTNERS clinical trial began patient enrollment in DRC on July 2, 2026, representing the first organized international effort to identify effective therapeutics specifically for Bundibugyo virus disease. [9]

HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius was published July 2, 2026; as of this posting, the multi-country outbreak remains under active monitoring. [10]
  • WHO Director-General personally thanked the people of Tenerife on May 14, 2026, for supporting the safe disembarkation and care of over 120 passengers from 23 countries during the outbreak response.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district: an adult male who developed neurological symptoms May 30 and was hospitalized June 10.
  • Earlier in 2026, two NiV-infected healthcare workers were confirmed in West Bengal (Barasat, North 24 Parganas district) in January, and one confirmed case was reported in Rajshahi Division, Bangladesh in February.

WEST NILE VIRUS — UNITED STATES

  • CDC warned on July 1, 2026, of an early and record-breaking West Nile virus season ahead of America's 250th Independence Day, urging use of EPA-registered repellents and elimination of standing water.

MPOX — RECOMBINANT STRAIN

  • WHO documented two cases globally of a recombinant mpox strain carrying genomic elements of both clade Ib and clade IIb MPXV as of February 14, 2026; recombination is a known natural process occurring when two viral strains co-infect one host.

MEASLES — BANGLADESH

  • Bangladesh notified WHO on April 4, 2026, of a nationwide measles surge affecting 58 of 64 districts, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across all eight divisions.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy confirmed a human case of avian influenza A(H9N2) on March 21, 2026, in an adult male returning from Senegal; next-generation sequencing confirmed the H9N2 subtype.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections with associated deaths; transmission activity in the Americas persisted from a 2025 surge into 2026.

SALMONELLA — MULTIPLE U.S. OUTBREAKS ONGOING

  • CDC warns that moringa leaf products are linked to a growing number of Salmonella outbreaks; as of January 29, 2026, 65 people across 28 states were affected, with extensively drug-resistant strains among cases.
  • A separate Salmonella outbreak linked to backyard poultry sickened 150 additional people as of May 14, 2026, with over a quarter of cases in children under age 5.

LISTERIA — REQUESÓN/SOFT RICOTTA CHEESE

  • CDC warned on June 5, 2026, of a Listeria monocytogenes outbreak linked to requesón/soft ricotta cheese, adding to several concurrent Listeria outbreak investigations active in 2025-2026.

INFANT BOTULISM — POWDERED FORMULA

  • CDC issued an outbreak update on June 13, 2026, urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to confirmed infant botulism cases.

NEW WORLD SCREWWORM — UNITED STATES

  • CDC activated its Emergency Operations Center on June 12, 2026, to coordinate the federal response to New World Screwworm (Cochliomyia hominivorax), a parasitic fly larva capable of infesting humans and livestock.

DRUG-RESISTANT BACTERIA — RISING THREAT

  • A CDC report released September 23, 2025, found a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing the urgency of antimicrobial stewardship programs.

🧬 LONGEVITY & AGING

SENESCENCE AND CARTILAGE BIOLOGY

  • A study in Regenerative Therapy (June 13, 2026) found that long-term expandable auricular chondrocytes reveal a conserved nine-gene decline module that drives dedifferentiation independently of senescence, suggesting senescence and tissue aging are partially separate biological processes.

NAD-PLUS RESTORATION FOR AGED BONE REPAIR

  • Researchers published in Bioactive Materials (June 27, 2026) a hierarchical scaffold that modulates senescent metabolism, restores NAD-plus homeostasis and redox balance, and significantly improved aged bone repair in preclinical models.

KAEMPFEROL AND LIFESPAN EXTENSION

  • A Toxicology Reports study (June 25, 2026) found that kaempferol derived from Moringa oleifera increased longevity and reduced efavirenz-induced functional senescence in Drosophila melanogaster, suggesting the flavonoid counters drug-accelerated aging.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

  • A Scandinavian Journal of Primary Health Care study (June 23, 2026) found an association between insulin resistance and both mild cognitive impairment and reduced health-related quality of life during aging, adding metabolic control to the dementia prevention toolkit.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two Lancet Healthy Longevity commentaries (Sipilä and Kivimäki; Penfold, Jiwaji, and MacLullich) propose that delirium following severe infection may represent the mechanistic link connecting acute infectious illness to long-term dementia risk.

CHRONIC KIDNEY DISEASE AND MULTI-MORBIDITY MORTALITY

  • The NURTuRE-CKD multicentre cohort study published in Annals of Medicine (June 23, 2026) found that multiple long-term conditions significantly worsened mortality, progression to kidney failure, and health-related quality of life in people with chronic kidney disease.

GUT MICROBIOME AND INTESTINAL FITNESS

  • A Gut Microbes paper (June 21, 2026) found that biofilm overproduction by Bacillus subtilis enhances gastrointestinal stress tolerance and intestinal fitness, a finding with potential relevance to probiotic design for aging guts.

METFORMIN AGING STUDY — ONGOING

  • ClinicalTrials.gov (NCT04264897) continues enrolment for the Antecedent Metabolic Health and Metformin Aging Study, testing the hypothesis that the anti-diabetic drug metformin can slow aging and prolong healthspan in humans.

PDE4 IMAGING IN ALZHEIMER DISEASE — ONGOING TRIAL

  • A NIH trial (NCT07169630) is enrolling adults with Alzheimer disease or mild cognitive impairment for PET imaging of phosphodiesterase-4, an inflammatory enzyme, to better understand neuroinflammation's role in dementia progression.

BIOLOGICAL AGE AND LIGHT THERAPY IN CANCER PATIENTS

  • ClinicalTrials.gov trial NCT07064395 is investigating whether bright light therapy can reduce sleep disturbance in lung cancer patients and also lower biological age as measured by clinical biomarkers.

PHYSICAL ACTIVITY RESTRICTION AND CEREBROVASCULAR MORTALITY — JAPAN

  • An ecological panel study across all 47 Japanese prefectures from 2013 to 2022 found that structural physical activity restriction was associated with higher cerebrovascular and diabetes mortality and greater long-term care intensity, with a COVID-19 counterfactual analysis amplifying these findings.

💊 NEW CURES & APPROVALS

LUMVOA (VELIGROTUG-VVZE) — VIRIDIAN THERAPEUTICS

  • FDA granted original approval (ORIG AP) to Viridian Therapeutics' LUMVOA (veligrotug-vvze), a new biologic agent, under BLA 761530; this is a first-in-class approval for this active ingredient.

BESREMI (ROPEGINTERFERON ALFA-2B-NJFT) — PHARMAESSENTIA CORP

  • PharmaEssentia received a supplemental approval (SUPPL AP) for BESREMI (ropeginterferon alfa-2b-njft) under BLA 761166, expanding indications for this interferon-based therapy.

ROMVIMZA (VIMSELTINIB) — DECIPHERA PHARMACEUTICALS

  • Deciphera Pharmaceuticals received a supplemental approval for ROMVIMZA (vimseltinib) under NDA 219304; vimseltinib is a CSF1R kinase inhibitor used in tenosynovial giant cell tumor.

ZEVTERA (CEFTOBIPROLE MEDOCARIL SODIUM) — ISTX

  • ISTX received a supplemental approval for ZEVTERA (ceftobiprole medocaril sodium) under NDA 218275; ceftobiprole is a fifth-generation cephalosporin antibiotic active against MRSA.

SARCLISA (ISATUXIMAB-IRFC) — SANOFI AVENTIS US

  • Sanofi Aventis received a supplemental approval for SARCLISA (isatuximab-irfc) under BLA 761113; isatuximab is an anti-CD38 monoclonal antibody indicated for multiple myeloma.

SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE INC

  • AbbVie received supplemental approvals for SKYRIZI (risankizumab-rzaa) under both BLA 761105 and BLA 761262; risankizumab is an IL-23 inhibitor used in plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease.

RINVOQ LQ (UPADACITINIB) — ABBVIE

  • AbbVie received a supplemental approval for RINVOQ LQ (upadacitinib liquid formulation) under NDA 218347; upadacitinib is a JAK1-selective inhibitor for immune-mediated conditions.

DAPSONE — ALEMBIC PHARMACEUTICALS

  • Alembic received original approval (ORIG AP) for generic dapsone under ANDA 213414, expanding affordable access to this antibiotic and anti-inflammatory agent used in dermatitis herpetiformis and leprosy.

🧪 CLINICAL TRIALS

PARTNERS TRIAL — BUNDIBUGYO VIRUS THERAPEUTICS (DRC, OPENED JULY 2, 2026)

  • WHO announced July 2, 2026, that the PARTNERS clinical trial opened patient enrollment in DRC to evaluate candidate therapeutics specifically for Bundibugyo virus disease (BVD), the first such trial for this pathogen. [9]

AMLITELIMAB PHASE 3 FOR ATOPIC DERMATITIS (NCT06241118)

  • A Phase 3, randomized, double-blind, placebo-controlled, multinational, 3-arm trial of subcutaneous amlitelimab (an anti-IL-33 receptor biologic) on background topical corticosteroids in participants aged 12 and older with moderate-to-severe atopic dermatitis who failed prior biologic or JAK inhibitor therapy was updated July 2, 2026.

METFORMIN AGING STUDY (NCT04264897)

  • The Antecedent Metabolic Health and Metformin Aging Study continues to test metformin as a pharmaceutical candidate to slow human aging; no pharmaceutical treatments to slow aging are currently approved, making this a landmark trial.

AMINO ACID SUPPLEMENTATION IN PARKINSON DISEASE (NCT07115563)

  • A clinical trial is evaluating whether a tailored amino acid supplement improves nutrition, metabolic function, body composition, and physical and mental function in adults living with Parkinson's disease.

MIRABEGRON AND ALPHA-LIPOIC ACID COMBINATION FOR OBESITY (NCT05713799)

  • A NIH trial is testing the combination of mirabegron (a beta-3 adrenergic agonist) and alpha-lipoic acid in men and women with obesity to assess safety, tolerability, and metabolic effects.

PDE4 PET IMAGING IN ALZHEIMER DISEASE AND MCI (NCT07169630)

  • The NIH trial using PET imaging of phosphodiesterase-4 in participants with Alzheimer disease or mild cognitive impairment aims to quantify neuroinflammation as a potential biomarker and therapeutic target.

AI-BASED FOOD INTAKE DETERMINANTS STUDY (NCT07637656)

  • A NIH trial is applying artificial intelligence to complex high-dimensional data to discover why some people gain weight easily while others resist weight gain despite similar caloric intake, with implications for personalized obesity interventions.

SPIRONOLACTONE IN ALCOHOL USE DISORDER (NCT05807139)

  • A NIH trial is evaluating spironolactone, a mineralocorticoid receptor antagonist already approved for cardiovascular indications, as a potential repurposed treatment for alcohol use disorder affecting approximately 29.5 million Americans.

BRIGHT LIGHT THERAPY AND BIOLOGICAL AGE IN LUNG CANCER (NCT07064395)

  • This randomized trial is testing whether bright light therapy reduces sleep disturbance and lowers biological age as measured by clinical biomarkers in lung cancer patients, bridging chronobiology and geroscience.

📢 PUBLIC HEALTH

WEST NILE VIRUS SEASON ALERT — USA

  • CDC reported on July 1, 2026, that weekly emergency room visits for mosquito bites are tracking above historical averages, with West Nile virus cases running at record early-season levels; CDC advises use of DEET-based repellents and removing standing water.

TICK BITE ER VISITS — ABOVE NORMAL

  • CDC reported on April 23, 2026, that weekly ER visits for tick bites are higher than usual for this point in the season, urging Americans to use tick repellents and perform full-body checks after outdoor activities.

CHILDHOOD IMMUNIZATION SCHEDULE — UPDATED JANUARY 2026

  • Acting CDC Director Jim O'Neill signed a decision memorandum on January 4, 2026, acting on a Presidential Memorandum to update the childhood immunization schedule; details of specific changes were not specified in the source document.

HEPATITIS B VACCINE — INDIVIDUAL-BASED DECISION FOR LOW-RISK INFANTS

  • CDC formally adopted on December 16, 2025, an individual-based decision-making framework for hepatitis B vaccination of infants born to women who test negative for hepatitis B virus, following an ACIP vote.

BIOSURVEILLANCE MILESTONE — AIR TRAVEL PROGRAM

  • CDC announced January 30, 2026, that its Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants, enhancing the nation's capacity to detect novel pathogens at ports of entry.

UNSAFE FOOD — GLOBAL BURDEN UPDATE

  • WHO estimated on June 4, 2026, that unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under age five facing nearly three times the illness risk of older individuals.

US-WHO WITHDRAWAL COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and politicization, with the administration pledging to pursue bilateral health partnerships instead.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  4. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  5. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  6. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  9. Patient enrolment begins in a scientific trial to identify the… — WHO News
  10. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260706-02-v19 · 2026-07-06 02:02 UTC · pulse.uzylab.com

Read next